Search results: Found 3

Listing 1 - 3 of 3
Sort by
Prozessintelligenz: Business-Process-Management-Studie – Status quo und Erfolgsmuster

Authors: --- ---
ISBN: 9783662557044 9783662557051 Year: Pages: 126 DOI: https://doi.org/10.1007/978-3-662-55705-1 Language: German
Publisher: Springer Grant: Zurich University of Applied Sciences
Subject: Business and Management
Added to DOAB on : 2018-06-29 15:38:37
License:

Loading...
Export citation

Choose an application

Abstract

Unternehmen im deutschsprachigen Raum verankern Prozessmanagement zunehmend in ihrer Organisation und richten es strategisch aus. Der Fokus liegt initial häufig auf der Schaffung von Transparenz. Doch unternehmensweite Prozesslandkarten und Prozessmodelle sind nur ein Abbild der Realität. Um die Wirksamkeit des Prozessmanagements zu erhöhen, braucht es eine Brücke zum operativen Geschäft. Prozessintelligenz bietet hierfür hilfreiche Ansatzpunkte. Die Process-Management-Studie 2015 des Instituts für Wirtschaftsinformatik an der Zürcher Hochschule für Angewandte Wissenschaften ZHAW School of Management and Law widmet sich diesem Thema und beleuchtet Status quo und Erfolgsmuster. In Fallstudien mit fünf Unternehmen werden Herausforderungen, Lösungsansätze und Nutzen von Prozessintelligenz aufgezeigt. Die Ergebnisse einer Online-Befragung zur Ausrichtung des Prozessmanagements und zum Methoden- und Werkzeugeinsatz bei Unternehmen komplettieren das Bild.

Towards Mechanism-based Treatments for Fragile X Syndrome

Authors: ---
ISBN: 9783039215058 / 9783039215065 Year: Pages: 250 DOI: 10.3390/books978-3-03921-506-5 Language: eng
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Science (General) --- Biology
Added to DOAB on : 2019-12-09 11:49:15
License:

Loading...
Export citation

Choose an application

Abstract

It has been more than 25 years since the identification of the FMR1 gene and the demonstration of the causative role of CGG-repeat expansion in the disease pathology of fragile X syndrome (FXS), but the underlying mechanisms involved in the expansion mutation and the resulting gene silencing still remain elusive. Our understanding of the pathways impacted by the loss of FMRP function has grown tremendously, and has opened new avenues for targeted treatments for FXS. However, the failure of recent clinical trials that were based on successful preclinical studies using the Fmr1 knockout mouse model has forced the scientific community to revisit clinical trial design and identify objective outcome measures. There has also been a renewed interest in restoring FMR1 gene expression as a possible treatment approach for FXS. This special issue of Brain Sciences highlights the progress that has been made towards understanding the disease mechanisms and how this has informed the development of treatment strategies that are being explored for FXS.

Keywords

fragile X syndrome --- clinical trials --- targeted treatments --- drug development --- fragile X syndrome --- clinical trials --- treatment development --- best practices --- fragile X syndrome --- newborn screening --- early identification --- fragile X syndrome --- X chromosome --- females --- FMR1 --- anxiety --- avoidance --- cognition --- behavior --- brain --- Fragile X --- FMRP --- Fxr2 --- Fmr1 --- fragile X syndrome --- executive function --- working memory --- set-shifting --- cognitive flexibility --- inhibitory control --- attention --- planning --- processing speed --- Fragile X syndrome 1 --- Fragile X-associated Tremor/Ataxia Syndrome 2 --- CRISPR 3 --- Trinucleotide Repeat 4 --- Gene editing --- fragile X syndrome --- FMR1 gene --- voice of the person --- voice of the patient --- characteristics that have the greatest impact --- developmental disorders --- fragile X syndrome --- language development --- automated vocal analysis --- adeno-associated virus --- autism spectrum disorders --- cerebral spinal fluid --- fragile X mental retardation protein --- neurodevelopmental disorders --- viral vector --- fragile X syndrome --- gene reactivation --- RNA:DNA hybrid --- FMRP --- histone methylation --- DNA methylation --- FMR1 --- PRC2 --- fragile X syndrome --- unstable repeat diseases --- epigenetic gene silencing --- DNA methylation --- repeat instability --- pluripotent stem cells --- CGG Repeat Expansion Disease --- DNA instability --- expansion --- contraction --- mismatch repair (MMR) --- base excision repair (BER) --- transcription coupled repair (TCR) --- double-strand break repair (DSBR) --- Non-homologous end-joining (NHEJ) --- mosaicism --- protein synthesis --- Fragile X Syndrome --- biomarker --- iPSC --- fibroblast --- lymphoblast --- fragile X syndrome --- molecular biomarkers --- FMR1 --- FMRP --- intellectual disability --- Fmr1 KO mouse --- ASD --- n/a

Hurdles for Phage Therapy (PT) to Become a Reality

Author:
ISBN: 9783039213917 / 9783039213924 Year: Pages: 484 DOI: 10.3390/books978-3-03921-392-4 Language: eng
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Science (General) --- Biology --- Microbiology
Added to DOAB on : 2019-12-09 11:49:15
License:

Loading...
Export citation

Choose an application

Abstract

Alternative treatment modes for antibiotic-resistant bacterial pathogens have become a public health priority. Bacteriophages are bacterial viruses that infect and lyse bacterial cells. Since bacteriophages are frequently bacterial host species-specific and can often also infect antibiotic-resistant bacterial cells, they could represent ideal antimicrobials for fighting the antibiotic resistance crisis. The medical use of bacteriophages has become known as phage therapy. It is widely used in Russia, where phage cocktails are sold in pharmacies as an over-the-counter drug. However, no phage product has been registered for medical purposes outside of the former Soviet Union. The current Special Issue of Viruses contains a collection of papers from opinion leaders in the field who explore hurdles to the introduction of phage therapy in western countries. The articles cover diverse topics ranging from patent to regulatory issues, the targeting of suitable bacterial infections, and the selection and characterization of safe and efficient phage cocktails. Phage resistance is discussed, and gaps in our knowledge of phage–bacterium interactions in the mammalian body are revealed, while other articles explore the use of phages in food production and processing.

Keywords

Staphylococcus aureus --- bacteriophage --- phage therapy --- vB_SauM-fRuSau02 --- Twortlikevirus --- antibiotic --- antimicrobial resistance --- magistral preparation --- compounding pharmacy --- phage therapy --- regulatory framework --- personalized medicine --- bacteriophage --- phage --- horizontal gene transfer --- co-evolution --- phage therapy --- industrial phage application --- antimicrobial resistance (AMR) --- Germany --- pH stability --- phage-host interactions --- genomics --- antibiotic-resistance --- phage preparation --- lysins --- biofilms --- typhoid fever --- Salmonella Typhi --- extended-spectrum beta lactamases (ESBL) --- Democratic Republic of the Congo --- bacteriophages --- MALDI-MS --- Staphylococcus --- bacteriophages --- phage therapy --- Kayvirus --- Viral proteins --- bacteriophage --- therapy --- phage therapy --- bacterial disease --- infection --- target selection --- Bacteriophage --- phage therapy --- resistance --- adaptation --- prophage --- production --- regulation --- phage therapy --- viral genomes --- best practices --- IND --- high-throughput sequencing --- bacteriophages --- phages --- food safety --- foodborne illness --- phage therapy --- history of science --- science communication --- bacteriophage --- phage therapy --- sustainable agriculture --- zoonosis --- antibiotic resistance --- phage therapy --- experimental therapy --- phage cocktails --- anti-phage antibodies --- prophage --- immunomodulation --- phage therapy --- evolution --- bacterial resistance --- virulence --- Listeria ivanovii --- bacteriophages --- alginate --- production --- disinfection --- phagodisinfection --- virus–host interactions --- bacteriophage efficacy --- gastrointestinal tract --- phage therapy --- bacteriophage --- phage therapy --- antimicrobial resistance --- antibiotic --- global health --- developing countries --- infectious disease --- bacteriophage --- phage --- phage therapy --- phage-resistance --- phage therapy --- bacterial infection --- capsule depolymerase --- antibiotic --- animal model --- bacterial resistance --- bacteriophage --- immunology --- innate immunity --- adaptive immunity --- human host --- phage-human host interaction --- bacterial infection --- antibiotic resistance --- bacteriophage --- antibiotic therapy --- phage therapy --- cases report --- abortive infection --- prophage --- adsorption --- Enterococcus --- rhamnopolysaccharide --- bacteriophage --- phage therapy --- Staphylococcus aureus --- biofilm --- antimicrobial --- frequency of resistance --- phage sensitivity --- resistance management --- nontraditional antibacterial --- bacteriophages --- phage therapy --- antibiotic resistance --- Pseudomonas aeruginosa --- Escherichia coli --- Staphylococcus aureus --- Brussels --- Belgium --- phage biocontrol --- patent landscape --- crop production --- bacteriophage --- phage therapy --- multidrug-resistant bacteria --- antimicrobial resistance --- bacteriophage therapy --- compassionate use --- antibiotic resistance --- phage therapy --- PTMP --- ATMP --- regulatory framework --- pharmaceutical paradigm shift --- clinical trial --- magistral formula --- personalized medicine --- phage therapy --- E. faecalis --- OrthoMCL --- antimicrobial resistance --- capsule --- Galleria mellonella --- Klebsiella pneumoniae --- phage therapy --- n/a --- antimicrobial resistance --- bacteriophage --- personalised medicines --- phage therapy --- pharmaceutical legislation --- regulatory framework

Listing 1 - 3 of 3
Sort by
Narrow your search

Publisher

MDPI - Multidisciplinary Digital Publishing Institute (2)

Springer (1)


License

CC by-nc-nd (2)

CC by (1)


Language

eng (2)

german (1)


Year
From To Submit

2019 (2)

2018 (1)